• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • What do meta-analyses tell us about clozapine's efficacy and effectiveness for treatment refractory schizophrenia?

    Thumbnail
    View/Open
    Kisely205235-Published.pdf (92.06Kb)
    File version
    Version of Record (VoR)
    Author(s)
    Siskind, Dan
    Kisely, Steve
    Land, Rachel
    McCartney, Lara
    Griffith University Author(s)
    Kisely, Steve R.
    Year published
    2018
    Metadata
    Show full item record
    Abstract
    Background Clozapine has long been considered the gold standard antipsychotic for treatment refractory schizophrenia (TRS). There have been a number of recent meta-analyses of efficacy of clozapine on psychotic symptoms and effectiveness in reducing hospitalisations that have sparked debate on the role of clozapine. Methods Current literature regarding the efficacy of clozapine for TRS, including pair-wise and network meta-analyses of RCTs with reported outcomes of total psychotic symptoms, positive symptoms and negative symptoms were reviewed. We also examined the results of a meta-analysis of the effectiveness of clozapine ...
    View more >
    Background Clozapine has long been considered the gold standard antipsychotic for treatment refractory schizophrenia (TRS). There have been a number of recent meta-analyses of efficacy of clozapine on psychotic symptoms and effectiveness in reducing hospitalisations that have sparked debate on the role of clozapine. Methods Current literature regarding the efficacy of clozapine for TRS, including pair-wise and network meta-analyses of RCTs with reported outcomes of total psychotic symptoms, positive symptoms and negative symptoms were reviewed. We also examined the results of a meta-analysis of the effectiveness of clozapine on reducing hospitalisations based in RCTs and observational studies. Results Two recent meta-analyses: Samara et al (2016), a network meta-analysis in JAMA Psychiatry; and Siskind et al (2016) a pairwise meta-analysis in BJPsych, found similar equivocal results for total psychotic symptoms. However, Siskind et al (2016) found clozapine to be superior to other anti-psychotics for positive symptoms. Factors influencing the difference in results included pair-wise vs network methodology and sensitivity analyses of pharmaceutical industry support. Of note, only 40% of people with TRS responded to clozapine. Clozapine’s effectiveness for reducing hospitalisations was significant, with a relative risk of 0.74 (95%CI 0.69–0.80). Discussion There are a lack of recent non-industry funded randomised control trials of clozapine compared to SGAs, which hinders an equivocal statement about the superiority of clozapine for total psychotic symptoms. However, there is evidence to suggest that clozapine is superior to other antipsychotics, including SGAs, for positive symptoms. In terms of effectiveness, initiation of clozapine can reduce the proportion of people hospitalised and reduce bed days. Use of clozapine needs to be balanced against its adverse drug reaction profile. There remains a need for more effective treatments for TRS, and biomarkers to identify TRS.
    View less >
    Conference Title
    Schizophrenia Bulletin
    Volume
    44
    Issue
    suppl_1
    DOI
    https://doi.org/10.1093/schbul/sby014.169
    Copyright Statement
    © Maryland Psychiatric Research Center 2018. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
    Subject
    Biomedical and clinical sciences
    Psychology
    Science & Technology
    Life Sciences & Biomedicine
    Psychiatry
    Publication URI
    http://hdl.handle.net/10072/411811
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander